Aurora Cannabis to Buy CanniMed Therapeutics in Friendly Deal Valued at $1.1B

Under the agreement, Aurora has agreed to pay $43 per share in stock and cash for each CanniMed share.
Under the agreement, Aurora has agreed to pay $43 per share in stock and cash for each CanniMed share. (Image via Canadian Press)

EDMONTON — Aurora Cannabis Inc. has struck a friendly deal valued at $1.1 billion to buy rival licensed producer CanniMed Therapeutics Inc., bringing an end to a hostile takeover battle between the marijuana companies.

Under the agreement, Aurora has agreed to pay $43 per share in stock and cash for each CanniMed share.

That’s up from its earlier hostile offer of $24 per share for the company that Aurora had made late last year.

The new offer and the transaction are subject to customary closing conditions, including Competition Act approval.

The deal also means CanniMed will abandon its plans to acquire Newstrike Resources Ltd.

CanniMed will pay a $9.5-million break fee to Newstrike as a result of its decision.

Companies in this story: (TSX:CMD, TSX:ACB, TSXV:HIP)

The Canadian Press

Comments